Mycophenolic acid in diabetic renal transplant recipients: Pharmacokinetics and application of a limited sampling strategy

Therapeutic Drug Monitoring

Volumn 26, Issue 6, 2004, Pages 620-625

  Van Hest, Reinier M ^a   Mathôt, Ron A A ^a   Vulto, Arnold G ^a   Meur, Yann Le ^b   Van Gelder, Teun ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

Diabetes mellitus; Limited sampling strategy; Mycophenolic acid; Pharmacokinetics

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; MYCOPHENOLIC ACID;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DRUG EFFECT; DRUG MONITORING; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TECHNIQUE; VALIDATION PROCESS;

ADULT; AGED; AREA UNDER CURVE; CONFIDENCE INTERVALS; DIABETES MELLITUS; DRUG MONITORING; FEMALE; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; LINEAR MODELS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES; SAMPLING STUDIES; STATISTICS, NONPARAMETRIC;

EID: 9644281481     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200412000-00006     Document Type: Article

References (22)

1. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet. 1995;345:1321-1325.
2. Van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenoalte mofetil for the prevention of acute rejection after kidney transplantation. Transplantation. 1999;68:261-266.
3. Mourad M, Malaise J, Chaib Eddour D, et al. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clin Chem. 2001;47:1241-1248.
4. Shaw LM, Holt DW, Oellerich M, et al. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit. 2001;23:305-315.
5. Shaw LM, Korecka M, Venkataramanan R, et al. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant. 2003;3:534-542.
6. Willis C, Taylor PJ, Salm P, et al. Evaluation of limited sampling strategies for estimation of 12-hour mycophenolic acid area under the plasma concentration-time curve in adult renal transplant patients. Ther Drug Monit. 2000;22:549-554.
7. Pawinski T, Hale M, Korecka M, et al. Limited sampling strategy for the estimation of mycophenolie acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem. 2002;48:1497-1504.
8. Filler G, Mai I. Limited sampling strategy for mycophenolic acid area under the curve. Ther Drug Monit. 2000;22:169-173.
9. Johnson AG, Rigbey RJ, Taylor PJ, et al. The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients. Clin Pharmacol Ther. 1999;66:492-500.
10. Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokinetic- pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther. 1998;64:672-683.
11. Shaw LM, Korecka M, Aradhye S, et al. Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable. J Clin Pharmacol. 2000;40:624-633.
12. Taylor PJ, Willis C, Salm P, et al. Accurate estimation of mycophenolic acid AUC (letter). Ther Drug Monit. 2001;23:301-302.
13. Gwilt PR, Nahhas RR, Tracewell WG. The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmacokinet. 1991;20:477-490.
14. Tsina I, Chu F, Hama K, et al. Manual and automated (robotic) high-performance liquid chromatography methods for the determination of mycophenolic acid and its glucuronide conjugate in human plasma. J Chromatogr B Biomed Appl. 1996;675:119-129.
15. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503-512.
16. Bland M, Altman DG. Statistical methods for assessing agreement between methods of clinical measurement. Lancet. 1986;1:307-310.
17. Altman DG. Practical statistics for medical research. London: Chapman & Hall, 1999:455-461.
18. Viberti G. Diabetes mellitus: a major challenge in transplantation. Transplant Proc 2001;33[suppl 5A]:3S-7S.
19. Talley NJ. Diabetic gastropathy and prokinetics. Am J Gastroenterol. 2003;98:264-271.
20. David OJ, Johnston A. Limited sampling strategies for estimating cyclosporin area under the concentration-time curve: review of current algorithms. Ther Drug Monit. 2001;23:100-114.
21. Schütz A, Armstrong VW, Shipkova M, et al. Limited sampling strategy for the determination of mycophenolie acid area under the curve in pediatric kidney recipients. Transplant Proc. 1998;30:1182-1184.
22. Yeung S, Tong KL, Tsang WK, et al. Determination of mycophenolate area under the curve by limited sampling strategy. Transplant Proc. 2001;33:1052-1053.